Business Description
Genetic Technologies Ltd
NAICS : 325414
SIC : 2836
ISIN : AU000000GTG7
Description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Beneish M-Score | -5.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 287.1 | |||||
| 3-Year EBITDA Growth Rate | -3.3 | |||||
| 3-Year FCF Growth Rate | 3.8 | |||||
| 3-Year Book Growth Rate | -61.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 94.26 | |||||
| 9-Day RSI | 88.85 | |||||
| 14-Day RSI | 82.48 | |||||
| 6-1 Month Momentum % | -4.85 | |||||
| 12-1 Month Momentum % | -51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.88 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | -1.66 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -81.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PS Ratio | 0.67 | |||||
| PB Ratio | 2.79 | |||||
| EV-to-EBIT | -0.46 | |||||
| EV-to-EBITDA | -0.48 | |||||
| EV-to-Revenue | 0.72 | |||||
| EV-to-FCF | -0.87 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.25 | |||||
| Earnings Yield (Greenblatt) % | -217.39 | |||||
| FCF Yield % | -111.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genetic Technologies Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4.728 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 1.6 | ||
| Volatility % | 195.02 | ||
| 14-Day RSI | 82.48 | ||
| 14-Day ATR (€) | 0.000267 | ||
| 20-Day SMA (€) | 0.049 | ||
| 12-1 Month Momentum % | -51 | ||
| 52-Week Range (€) | 0.011 - 0.112 | ||
| Shares Outstanding (Mil) | 145.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genetic Technologies Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genetic Technologies Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genetic Technologies Ltd Frequently Asked Questions
What is Genetic Technologies Ltd(FRA:DU8)'s stock price today?
The current price of FRA:DU8 is €0.05. The 52 week high of FRA:DU8 is €0.11 and 52 week low is €0.01.
When is next earnings date of Genetic Technologies Ltd(FRA:DU8)?
The next earnings date of Genetic Technologies Ltd(FRA:DU8) is .
Does Genetic Technologies Ltd(FRA:DU8) pay dividends? If so, how much?
Genetic Technologies Ltd(FRA:DU8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers